6/21/2010

Patients with rheumatoid arthritis demonstrated significant reduction in knee pain and improvement in physical function after receiving one of three doses of Pfizer's injectable biotech drug tanezumab during a late-stage trial. The medicine targets nerve growth factor, a protein associated with pain.

Full Story:
Reuters

Related Summaries